Insider trade

CFO sold ~$2.67M of MRNA shares in the open market

Traded Sep 10, 2026 · Filed Sep 14, 2026

ModernaMRNA

~$2.67M
Reported value · 20K sh @ $134.49: 74K
Holds after · shares reported: +38.3%
stock since the trade · S&P 500 +0.8%, $136.62 → $188.94 on Oct 1

Why it stands out

The money chief of Moderna sold $2.67M of Moderna shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Sep 10, 2026
Reporting period: Not applicable
Filed with the SEC: Sep 14, 2026

CFO$1M+Pre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$2,667,744

Shares × reported transaction price

Timing vs results

41 days after results of Jul 31, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $136.62 on Sep 10, 2026, 511% above its 52-week low and 22% below its high, after a 151% rise over the previous 30 trading days

52-week range $22.36 (Nov 20, 2025) to $174.38 (Aug 19, 2026), 75% of the way up, from 251 adjusted closes. 30 trading days earlier: $54.49 on Jul 29, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Aug 9, 2024 in the U.S. District Court, D. Massachusetts. A filing is an allegation, not a finding.

Wentz v. Moderna, Inc., docket 1:24-cv-12058, via CourtListener (court records). Nature of suit 850, company named as first defendant